Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Conditions
Keywords
recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, secondary myelodysplastic syndromes, atypical chronic myeloid leukemia, breakpoint cluster region-Abelson (BCR-ABL) negative, refractory chronic lymphocytic leukemia, stage III chronic lymphocytic leukemia, stage IV chronic lymphocytic leukemia, accelerated phase chronic myelogenous leukemia, blastic phase chronic myelogenous leukemia, chronic phase chronic myelogenous leukemia, relapsing chronic myelogenous leukemia, stage II multiple myeloma, stage III multiple myeloma, primary systemic amyloidosis, refractory multiple myeloma, myelodysplastic/myeloproliferative neoplasm, unclassifiable, chronic eosinophilic leukemia, primary myelofibrosis, chronic neutrophilic leukemia, essential thrombocythemia, polycythemia vera, chronic myelomonocytic leukemia, acute undifferentiated leukemia, extramedullary plasmacytoma, isolated plasmacytoma of bone, monoclonal gammopathy of undetermined significance, stage I multiple myeloma, secondary acute myeloid leukemia, adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), nodal marginal zone B-cell lymphoma, noncontiguous stage II adult Burkitt lymphoma, noncontiguous stage II adult diffuse large cell lymphoma, noncontiguous stage II adult diffuse mixed cell lymphoma, noncontiguous stage II adult diffuse small cleaved cell lymphoma, noncontiguous stage II adult immunoblastic large cell lymphoma, noncontiguous stage II adult lymphoblastic lymphoma, noncontiguous stage II grade 1 follicular lymphoma, noncontiguous stage II grade 2 follicular lymphoma, noncontiguous stage II grade 3 follicular lymphoma, noncontiguous stage II mantle cell lymphoma, noncontiguous stage II marginal zone lymphoma, noncontiguous stage II small lymphocytic lymphoma, recurrent adult Burkitt lymphoma, recurrent adult Hodgkin lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent cutaneous T-cell non-Hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, splenic marginal zone lymphoma, stage III adult Burkitt lymphoma, stage III adult Hodgkin lymphoma, stage III adult diffuse large cell lymphoma, stage III adult diffuse mixed cell lymphoma, stage III adult diffuse small cleaved cell lymphoma, stage III adult immunoblastic large cell lymphoma, stage III adult lymphoblastic lymphoma, stage III grade 1 follicular lymphoma, stage III grade 2 follicular lymphoma, stage III grade 3 follicular lymphoma, stage III mantle cell lymphoma, stage III marginal zone lymphoma, stage III small lymphocytic lymphoma, stage IV adult Burkitt lymphoma, stage IV adult Hodgkin lymphoma, stage IV adult diffuse large cell lymphoma, stage IV adult diffuse mixed cell lymphoma, stage IV adult diffuse small cleaved cell lymphoma, stage IV adult immunoblastic large cell lymphoma, stage IV adult lymphoblastic lymphoma, stage IV grade 1 follicular lymphoma, stage IV grade 2 follicular lymphoma, stage IV grade 3 follicular lymphoma, stage IV mantle cell lymphoma, stage IV marginal zone lymphoma, stage IV small lymphocytic lymphoma, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
Brief summary
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after the transplant may stop this from happening. PURPOSE: This phase I/II trial is studying the side effects of giving busulfan and fludarabine together with total-body irradiation and to see how well they work in treating patients who are undergoing a donor stem cell transplant for hematologic cancer.
Detailed description
OBJECTIVES: Primary * To assess safety and toxicity of the addition of busulfan added to an established fludarabine and low-dose total-body irradiation (TBI) conditioning regimen for non-myeloablative allogeneic transplantation in patients with hematologic malignancies. (Phase I) * To assess the non-relapse mortality 1-year after conditioning with busulfan and fludarabine/TBI in patients with hematologic malignancies at moderate to high risk for graft rejection and/or relapse of underlying disease. (Phase II) Secondary * To assess overall survival 1-year survival. (Phase II) * To assess the incidence of graft rejection. (Phase II) * To assess the incidence of grade II-IV acute graft-vs-host disease (GVHD) and chronic extensive GVHD. (Phase II) * To assess rates of disease progression and/or relapse-related mortality. (Phase II) * To determine non-hematologic grade III-IV organ specific toxicity. (Phase II) OUTLINE: * Nonmyeloablative-conditioning regimen: Patients receive busulfan IV on day -5 and fludarabine IV over 30 minutes on days -4 to -2. Patients undergo total body irradiation on day 0. * Allogeneic peripheral blood stem cell transplantation (PBSC): Patients undergo donor PBSC infusion on day 0. * Graft-versus-host disease prophylaxis: Patients receive oral cyclosporine twice daily on days -3 to 56 followed by a taper to day 180. Patients with a related stem cell donor receive oral mycophenolate mofetil twice daily on days 0-28. Patients with an unrelated stem cell donor receive oral mycophenolate mofetil 3 times daily on days 0-28 followed by a taper twice daily to day 56. Patients with evidence of relapse or persistent disease may also receive up to 3 donor lymphocyte infusions. PROJECTED ACCRUAL: A total of 225 patients will be accrued for this study; 25 patients accrued into the Phase I and 200 patients into Phase II.
Interventions
BIOLOGICALtherapeutic allogeneic lymphocytes
A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
DRUGbusulfan
Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative. IV busulfan is available and diluted and administered per package insert guidelines.
DRUGcyclosporine
Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including Interleukin 2 (IL-2) and Interleukin 4 (IL-4). \- Starting on day -3, Cyclosporine (CSP) is given at a dose of 4.0 mg/kg p.o. b.i.d.
DRUGfludarabine phosphate
Fludarabine's active metabolite 2-fluoro-ara-A is an antimetabolite that inhibits DNA primase, DNA polymerase alpha and ribonucleotide nuclease. * Dosing: Days -4, -3 and -2: Fludarabine 30 mg/m2/day IV. Total dose equals 90 mg/m2. * Monitoring: Fludarabine level is not monitored. * Dose Adjustments: There are no provisions for fludarabine dose adjustments.
DRUGmycophenolate mofetil
Mycophenolate mofetil (MMF) is the morpholinyl ethyl ester of mycophenolic acid (MPA) and reversibly inhibits inosine monophosphate dehydrogenase, particularly the type II isoform that is more prominent in activated lymphocytes. As a result of the inhibition of de novo purine synthesis, proliferation of B- and T-lymphocytes is blocked and antibody production is inhibited. * Related Donors: MMF will be given daily at 15mg/kg q 12 hrs until day +28, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg). * Unrelated Donors: MMF will be given daily at 15mg/kg q 8 hrs until day +28, then given daily at 15mg/kg q 12 hours until day +56, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg).
PROCEDUREperipheral blood stem cell transplantation
Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or radiation therapy. There are three types of transplants: * In autologous transplants, patients receive their own stem cells. * In syngeneic transplants, patients receive stem cells from their identical twin. * In allogeneic transplants, patients receive stem cells from their brother, sister, or parent. A person who is not related to the patient (an unrelated donor) also may be used.
RADIATIONTotal Body Irradiation (TBI)
TBI is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell (or bone marrow) transplantation. As the name implies, TBI involves irradiation of the entire body, though in modern practice the lungs are often partially shielded to lower the risk of radiation-induced lung injury. * Toxicities: At the dosage used, side effects are not expected. Nevertheless, there may be fever, alopecia, parotitis, diarrhea, reversible skin pigmentation, mucositis and late effects including cataract formation, pulmonary damage, carcinogenesis, and sterilization. * Dosing: TBI will be given in one 200 cGy fraction from linear accelerator at a rate of 15-19 cGy/min.
Granulocyte colony-stimulating factor (G-CSF or GCSF) is a colony-stimulating factor hormone. G-CSF is also known as colony-stimulating factor 3 (CSF 3). It is a glycoprotein, growth factor and cytokine produced by a number of different tissues to stimulate the bone marrow to produce granulocytes and stem cells. G-CSF then stimulates the bone marrow to release them into the blood. * Toxicities: At the dosage used, the most common side effect will be medullary bone pain. * Dosing: 5 mcg/kg/day given per institutional standards (on approximately days 10-15 or not at all).
DRUGPhenytoin
This drug is used to prevent seizures while on chemotherapy.
DRUGMethotrexate
Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments.
Sponsors
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of a hematologic malignancy of 1 of the following high-risk types: * Acute lymphoblastic leukemia * Acute myeloid leukemia * Chronic myelogenous leukemia * Chronic lymphocytic leukemia * Myelodysplastic syndromes * Myeloproliferative disorder * Multiple myeloma * Plasma cell dyscrasias * Non-Hodgkin lymphoma * Hodgkin disease PATIENT CHARACTERISTICS: Performance status * Karnofsky 50-100% Life expectancy * Not specified Hematopoietic * Not specified Hepatic * No liver failure * No cirrhosis with evidence of portal hypertension * No alcoholic hepatitis * No esophageal varices * No chronic hepatitis * No other liver disease Renal * Not specified Cardiovascular * Left Ventricular Ejection Fraction (LVEF) \> 35% * No symptomatic coronary artery disease or cardiac failure requiring therapy Pulmonary * Diffusing capacity of lung for carbon monoxide (DLCO) \> 30% * Total lung capacity \> 30% * Forced expiratory volume in 1 second (FEV\_1) \> 30% * No supplementary continuous oxygen Other * HIV negative * No active nonhematologic malignancy except localized skin cancer * No overt organ dysfunction PRIOR CONCURRENT THERAPY: * Not specified
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Regimen-Related Toxicities | 5 years post-transplant | Non-hematologic toxicities and adverse experiences ≥ Grade 3 occurrences measured up to day +100 using the NCI Common Toxicity Criteria for Adverse Events v3.0 (CTCAE). Infections and GVHD will be assessed up to 5 years post transplant. The following data represents the number of regimen-related, grade 3 and 4 toxicities that occurred in each category. |
| Non-relapse Mortality | Two years post-transplant | Percent of subjects with non-relapse mortality two years after conditioning with busulfan with fludarabine/200 cGy TBI in patients with hematologic malignancies at moderate to high risk for graft rejection and/or relapse of underlying disease. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Relapse Mortality | Years 1 and 2 | The percentage of patients (out of 147 participants) who relapsed at Years 1 and 2. Relapse is defined as the presence of \>5% blasts by morphology on a post-transplant bone marrow aspirate. |
| Overall Survival | Years 1, 2, 3 and 5 | The percentage of overall patient survival (out of 147 participants) for Years 1, 2, 3 and 5. |
| Chronic Graft-Versus-Host Disease (cGVHD) Outcome | Years 1, 2 and 3 | Grading of Chronic GVHD: Limited: Localized skin involvement and/or hepatic dysfunction due to chronic GVHD Extensive: One or more of the following: Generalized skin involvement Liver histology showing chronic aggressive hepatitis, bridging necrosis or cirrhosis Involvement of the eye: Schirmer's test with \<5 mm wetting Involvement of minor salivary glands or oral mucosa demonstrated on labial biopsy Involvement of any other target organ Chronic GVHD Severity: Mild: Signs and symptoms of cGVHD do not interfere substantially with function and do not progress once appropriately treated with local therapy or standard systemic therapy. Moderate: Signs and symptoms of cGVHD interfere somewhat with function despite appropriate therapy or are progressive through first line systemic therapy. Severe: Signs and symptoms of cGVHD limit function substantially despite appropriate therapy or are progressive through second line systemic therapy |
| Acute Graft-Versus-Host Disease (aGVHD) Outcome | Day 100, Month 6 | Grading of Acute GVHD: Severity of Individual Organ Involvement: Skin * 1 a maculopapular eruption involving less than 25% of the body surface * 2 a maculopapular eruption involving 25-50% of the body surface * 3 generalized erythroderma * 4 generalized erythroderma with bullous formation and/or with desquamation Liver * 1 bilirubin 2.0-3.0mg/100mL * 2 bilirubin 3-5.9mg/100mL * 3 bilirubin 6-14.9mg/100mL * 4 bilirubin \>15mg/100mL Gut Diarrhea is graded +1 to +4 in severity. Nausea/vomiting and/or anorexia caused by GVHD is assigned as +1 in severity Diarrhea * 1 \<1000mL of liquid stool/day * 2 \>1,000mL of stool/day * 3 \>1,500mL of stool/day * 4 2,000mL of stool/day, severe abdominal pain, with or without ileus Severity of GVHD: Grade 1 +1 to +2 skin rash; No gut or liver involvement Grade 2 +1 to +3 skin rash;+1 GI involvement and/or +1 liver |
| Progression-Free Survival | Years 1, 2, 3, and 5 | The percentage of progression-free patients (out of 147 participants) at Years 1, 2, 3, and 5. Definition of Disease Progression: MM/Plasma Cell: Increasing bone pain or increase in serum/urine monoclonal protein by 25%. CLL/NHL/HD: New sites of lymphadenopathy; ≥ 25% increase in lymph node size; Blood or bone marrow involvement with clonal B-cells; Increase of ≥ 25% bone marrow involvement; ≥ 25% increase in blood involvement with clonal B-cells. AML/ALL: Any incidence of relapse (\>5% blasts) by evaluation of the bone marrow aspirate. CML: Inability to control platelet or granulocyte counts; Increase in baseline number of metaphases demonstrating the Ph+ chromosome by \>25%; Any other new cytogenetic abnormality; Transformation to accelerated phase or blast crisis. MDS/MPD: Any evidence by morphologic or flow cytometric evaluation of the bone marrow aspirate of new blasts (\>5%) or worsening cytopenia or cytogenetic evidence of recurrence. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0
Therapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
Busulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.
IV Busulfan is available and diluted and administered per package insert guidelines.
Cyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including | 147 |
| Total | 147 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Death | 17 |
Baseline characteristics
| Characteristic | Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 66 Participants |
| Age, Categorical Between 18 and 65 years | 81 Participants |
| Cytomegalovirus (CMV) Status All other combinations | 118 Participants |
| Cytomegalovirus (CMV) Status -/- recipient/donor | 22 Participants |
| Disease Risk Index (DRI) High or Very High | 51 Participants |
| Disease Risk Index (DRI) Low or intermediate | 93 Participants |
| Donor/Recipient Gender F/F, M/M, M/F | 117 Participants |
| Donor/Recipient Gender F/M | 30 Participants |
| Donor Relation Related Sibling Donor | 39 Participants |
| Donor Relation Unrelated Donor | 108 Participants |
| HLA Match 7/8 | 12 Participants |
| HLA Match 8/8 | 135 Participants |
| Karnofsky Performance Score (KPS) KPS < 90 | 48 Participants |
| Karnofsky Performance Score (KPS) KPS ≥ 90 | 91 Participants |
| Pre-Transplant Disease Status In Complete Remission | 85 Participants |
| Pre-Transplant Disease Status Not in Complete Remission | 62 Participants |
| Sex: Female, Male Female | 49 Participants |
| Sex: Female, Male Male | 98 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 52 / 147 |
| serious Total, serious adverse events | 59 / 147 |
Outcome results
Primary
Non-relapse Mortality
Percent of subjects with non-relapse mortality two years after conditioning with busulfan with fludarabine/200 cGy TBI in patients with hematologic malignancies at moderate to high risk for graft rejection and/or relapse of underlying disease.
Time frame: Two years post-transplant
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Non-relapse Mortality | Year 1 | 27 Participants |
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Non-relapse Mortality | Year 2 | 33 Participants |
Primary
Regimen-Related Toxicities
Non-hematologic toxicities and adverse experiences ≥ Grade 3 occurrences measured up to day +100 using the NCI Common Toxicity Criteria for Adverse Events v3.0 (CTCAE). Infections and GVHD will be assessed up to 5 years post transplant. The following data represents the number of regimen-related, grade 3 and 4 toxicities that occurred in each category.
Time frame: 5 years post-transplant
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Regimen-Related Toxicities | Respiratory Disorders | 8 Toxicities |
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Regimen-Related Toxicities | CNS Disorders | 16 Toxicities |
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Regimen-Related Toxicities | Hepatic Disorders | 39 Toxicities |
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Regimen-Related Toxicities | General Disorders | 30 Toxicities |
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Regimen-Related Toxicities | Cardiac Disorders | 21 Toxicities |
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Regimen-Related Toxicities | Renal Disorders | 10 Toxicities |
Secondary
Acute Graft-Versus-Host Disease (aGVHD) Outcome
Grading of Acute GVHD: Severity of Individual Organ Involvement: Skin * 1 a maculopapular eruption involving less than 25% of the body surface * 2 a maculopapular eruption involving 25-50% of the body surface * 3 generalized erythroderma * 4 generalized erythroderma with bullous formation and/or with desquamation Liver * 1 bilirubin 2.0-3.0mg/100mL * 2 bilirubin 3-5.9mg/100mL * 3 bilirubin 6-14.9mg/100mL * 4 bilirubin \>15mg/100mL Gut Diarrhea is graded +1 to +4 in severity. Nausea/vomiting and/or anorexia caused by GVHD is assigned as +1 in severity Diarrhea * 1 \<1000mL of liquid stool/day * 2 \>1,000mL of stool/day * 3 \>1,500mL of stool/day * 4 2,000mL of stool/day, severe abdominal pain, with or without ileus Severity of GVHD: Grade 1 +1 to +2 skin rash; No gut or liver involvement Grade 2 +1 to +3 skin rash;+1 GI involvement and/or +1 liver
Time frame: Day 100, Month 6
Population: This is cumulative incidence of grades 2-4 aGVHD at 100 days and at 6 months. Out of the total number of participants, grades 2-4 aGVHD occurred in 79 patients.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Acute Graft-Versus-Host Disease (aGVHD) Outcome | Day 100 | 55 percentage of analyzed participants |
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Acute Graft-Versus-Host Disease (aGVHD) Outcome | Month 6 | 60 percentage of analyzed participants |
Secondary
Chronic Graft-Versus-Host Disease (cGVHD) Outcome
Grading of Chronic GVHD: Limited: Localized skin involvement and/or hepatic dysfunction due to chronic GVHD Extensive: One or more of the following: Generalized skin involvement Liver histology showing chronic aggressive hepatitis, bridging necrosis or cirrhosis Involvement of the eye: Schirmer's test with \<5 mm wetting Involvement of minor salivary glands or oral mucosa demonstrated on labial biopsy Involvement of any other target organ Chronic GVHD Severity: Mild: Signs and symptoms of cGVHD do not interfere substantially with function and do not progress once appropriately treated with local therapy or standard systemic therapy. Moderate: Signs and symptoms of cGVHD interfere somewhat with function despite appropriate therapy or are progressive through first line systemic therapy. Severe: Signs and symptoms of cGVHD limit function substantially despite appropriate therapy or are progressive through second line systemic therapy
Time frame: Years 1, 2 and 3
Population: This is a cumulative incidence of cGVHD at 1 year, 2 years, and 3 years. A total of 99 patients (out of 147) developed cGVHD, 86 patients (87%) with extensive stage cGVHD and 13 patients (13%) with limited stage cGVHD.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Chronic Graft-Versus-Host Disease (cGVHD) Outcome | Year 2 | 66 percentage of analyzed participants |
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Chronic Graft-Versus-Host Disease (cGVHD) Outcome | Year 1 | 64.6 percentage of analyzed participants |
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Chronic Graft-Versus-Host Disease (cGVHD) Outcome | Year 3 | 67.3 percentage of analyzed participants |
Secondary
Overall Survival
The percentage of overall patient survival (out of 147 participants) for Years 1, 2, 3 and 5.
Time frame: Years 1, 2, 3 and 5
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Overall Survival | Year 1 | 60 percentage of analyzed participants |
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Overall Survival | Year 2 | 48 percentage of analyzed participants |
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Overall Survival | Year 3 | 42 percentage of analyzed participants |
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Overall Survival | Year 5 | 29 percentage of analyzed participants |
Secondary
Progression-Free Survival
The percentage of progression-free patients (out of 147 participants) at Years 1, 2, 3, and 5. Definition of Disease Progression: MM/Plasma Cell: Increasing bone pain or increase in serum/urine monoclonal protein by 25%. CLL/NHL/HD: New sites of lymphadenopathy; ≥ 25% increase in lymph node size; Blood or bone marrow involvement with clonal B-cells; Increase of ≥ 25% bone marrow involvement; ≥ 25% increase in blood involvement with clonal B-cells. AML/ALL: Any incidence of relapse (\>5% blasts) by evaluation of the bone marrow aspirate. CML: Inability to control platelet or granulocyte counts; Increase in baseline number of metaphases demonstrating the Ph+ chromosome by \>25%; Any other new cytogenetic abnormality; Transformation to accelerated phase or blast crisis. MDS/MPD: Any evidence by morphologic or flow cytometric evaluation of the bone marrow aspirate of new blasts (\>5%) or worsening cytopenia or cytogenetic evidence of recurrence.
Time frame: Years 1, 2, 3, and 5
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Progression-Free Survival | Year 1 | 48 percentage of analyzed participants |
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Progression-Free Survival | Year 2 | 39 percentage of analyzed participants |
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Progression-Free Survival | Year 3 | 35 percentage of analyzed participants |
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Progression-Free Survival | Year 5 | 29 percentage of analyzed participants |
Secondary
Relapse Mortality
The percentage of patients (out of 147 participants) who relapsed at Years 1 and 2. Relapse is defined as the presence of \>5% blasts by morphology on a post-transplant bone marrow aspirate.
Time frame: Years 1 and 2
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Relapse Mortality | Year 2 | 20 percentage of analyzed participants |
| Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI) | Relapse Mortality | Year 1 | 13 percentage of analyzed participants |